MARVEL BIOSCIENCES CORP (MRVL.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:MRVL - CA57384M1077 - Common Stock
MRVL.CA Key Statistics, Chart & Performance
The current stock price of MRVL.CA is 0.16 CAD. In the past month the price decreased by -13.51%. In the past year, price increased by 6.67%.
MRVL.CA Latest News, Press Relases and Analysis
About MRVL.CA
Company Profile
Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
Company Info
MARVEL BIOSCIENCES CORP
Suite 420, 505 8th Avenue S.W.
Calgary ALBERTA CA
Employees: 0
Phone: 14037702469
MARVEL BIOSCIENCES CORP / MRVL.CA FAQ
What does MRVL do?
Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
What is the stock price of MARVEL BIOSCIENCES CORP today?
The current stock price of MRVL.CA is 0.16 CAD.
Does MRVL stock pay dividends?
MRVL.CA does not pay a dividend.
How is the ChartMill rating for MARVEL BIOSCIENCES CORP?
MRVL.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is MARVEL BIOSCIENCES CORP worth?
MARVEL BIOSCIENCES CORP (MRVL.CA) has a market capitalization of 9.28M CAD. This makes MRVL.CA a Nano Cap stock.
MRVL.CA Technical Analysis
MRVL.CA Financial Highlights
Over the last trailing twelve months MRVL.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 29.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -322.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |